Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings

Raman VK, Vargas JD, Moore HJ, Wu WC, Patel SS, Zhang S, Morgan CJ, Lam PH, Heidenreich PA, Lu F, Ahmed AA, Fonarow GC, Ahmed A. Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings. Am J Med. 2026 Feb 21:S0002-9343(26)00079-3. doi: 10.1016/j.amjmed.2026.01.035. Epub ahead of print. PMID: 41724615.


Related Posts